Migdal Insurance & Financial Holdings Ltd. Acquires 621 Shares of Illumina, Inc. (ILMN)

Migdal Insurance & Financial Holdings Ltd. grew its holdings in shares of Illumina, Inc. (NASDAQ:ILMN) by 145.1% in the 3rd quarter, Holdings Channel reports. The firm owned 1,049 shares of the life sciences company’s stock after acquiring an additional 621 shares during the period. Migdal Insurance & Financial Holdings Ltd.’s holdings in Illumina were worth $385,000 as of its most recent SEC filing.

Other hedge funds have also added to or reduced their stakes in the company. Janney Montgomery Scott LLC increased its position in shares of Illumina by 10.0% during the second quarter. Janney Montgomery Scott LLC now owns 23,555 shares of the life sciences company’s stock valued at $6,579,000 after acquiring an additional 2,141 shares in the last quarter. Standard Life Aberdeen plc increased its position in shares of Illumina by 31.1% during the second quarter. Standard Life Aberdeen plc now owns 34,546 shares of the life sciences company’s stock valued at $9,650,000 after acquiring an additional 8,199 shares in the last quarter. Waters Parkerson & CO. LLC bought a new stake in shares of Illumina during the second quarter valued at approximately $223,000. Bank of Nova Scotia increased its position in shares of Illumina by 216.4% during the second quarter. Bank of Nova Scotia now owns 59,185 shares of the life sciences company’s stock valued at $16,529,000 after acquiring an additional 40,478 shares in the last quarter. Finally, Eqis Capital Management Inc. increased its position in shares of Illumina by 40.7% during the second quarter. Eqis Capital Management Inc. now owns 9,676 shares of the life sciences company’s stock valued at $2,702,000 after acquiring an additional 2,797 shares in the last quarter. Hedge funds and other institutional investors own 91.60% of the company’s stock.

Several equities research analysts recently weighed in on the stock. Zacks Investment Research downgraded shares of Illumina from a “buy” rating to a “hold” rating in a research report on Wednesday, October 24th. Barclays raised their price target on shares of Illumina from $350.00 to $370.00 and gave the company an “overweight” rating in a research report on Wednesday, October 24th. BidaskClub downgraded shares of Illumina from a “buy” rating to a “hold” rating in a research report on Tuesday, October 16th. Deutsche Bank raised their price target on shares of Illumina to $350.00 and gave the company a “buy” rating in a research report on Friday, October 12th. Finally, ValuEngine downgraded shares of Illumina from a “strong-buy” rating to a “buy” rating in a research report on Thursday, October 11th. Six investment analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company. The stock has a consensus rating of “Buy” and an average price target of $330.94.

In other news, insider Francis A. Desouza sold 2,100 shares of Illumina stock in a transaction on Monday, October 1st. The shares were sold at an average price of $369.61, for a total transaction of $776,181.00. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Jay T. Flatley sold 3,300 shares of Illumina stock in a transaction on Wednesday, November 14th. The stock was sold at an average price of $312.50, for a total transaction of $1,031,250.00. Following the transaction, the director now owns 376,710 shares in the company, valued at approximately $117,721,875. The disclosure for this sale can be found here. In the last ninety days, insiders sold 66,764 shares of company stock valued at $22,060,881. 0.54% of the stock is currently owned by insiders.

NASDAQ:ILMN opened at $309.88 on Friday. The company has a quick ratio of 2.24, a current ratio of 2.46 and a debt-to-equity ratio of 0.24. Illumina, Inc. has a 12 month low of $207.51 and a 12 month high of $372.61. The company has a market capitalization of $45.55 billion, a price-to-earnings ratio of 77.47, a P/E/G ratio of 2.30 and a beta of 1.07.

Illumina (NASDAQ:ILMN) last posted its earnings results on Tuesday, October 23rd. The life sciences company reported $1.52 EPS for the quarter, topping analysts’ consensus estimates of $1.26 by $0.26. Illumina had a net margin of 21.09% and a return on equity of 27.10%. The business had revenue of $853.00 million during the quarter, compared to the consensus estimate of $825.65 million. During the same quarter in the previous year, the firm posted $1.11 EPS. The firm’s revenue was up 19.5% on a year-over-year basis. On average, sell-side analysts forecast that Illumina, Inc. will post 5.75 earnings per share for the current year.

WARNING: This story was originally reported by WKRB News and is owned by of WKRB News. If you are viewing this story on another website, it was stolen and republished in violation of United States & international copyright and trademark law. The legal version of this story can be read at https://www.wkrb13.com/2018/11/23/migdal-insurance-financial-holdings-ltd-acquires-621-shares-of-illumina-inc-ilmn.html.

Illumina Profile

Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing by synthesis technology that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as allow the detection of known genetic markers on a single array.

Featured Story: Stock Selection – What is cash flow?

Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN).

Institutional Ownership by Quarter for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply